Biopharma companies have long struggled to identify the best responders for specific drugs.  Fortunately, data availability and technological advancements are now advanced enough for machine learning to help predict patient response using causal AI. The implications of correctly identifying markers of patient response are huge and include improved clinical trials design, timely patient recruitment, data and models for better supporting HTA and other market access submissions, reducing the cost of care and saving lives.

View this webinar, to hear why our distinguished speaker Dr. Alan Venook, Former Chair of the Alliance for Clinical Trials in Oncology, Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California-San Francisco, chose to join forces with GNS Healthcare and how together, they used GNS’ causal AI platform to better understand treatment response in metastatic colorectal cancer patients.

View Content.